Results 111 to 120 of about 852 (150)

Evinacumab for Homozygous Familial Hypercholesterolemia

New England Journal of Medicine, 2020
Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null-null) or impaired (non-null) LDL-receptor activity.
Daniel Gaudet, , Robert Pordy
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Evinacumab for the treatment of homozygous familial hypercholesterolemia

Expert Review of Clinical Pharmacology, 2022
Hypercholesterolemia is mainly caused by abnormal lipoprotein metabolism and can increase the risk of cardiovascular disease. Angiopoietin-like protein 3 (ANGPTL3) can increase low-density lipoprotein cholesterol (LDL-C) and other lipids by inhibiting lipoprotein lipase activity.
Junyi Yang
exaly   +3 more sources

Evinacumab for treatment of familial hypercholesterolemia

Expert Review of Cardiovascular Therapy, 2021
Introduction: Familial hypercholesterolemia (FH) is characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C), early onset coronary atherosclerosis, and premature death. FH is underdiagnosed and undertreated, but requires aggressive LDL-C-lowering to prevent complications.
Bruce Warden, P Barton Duell
exaly   +3 more sources

Evinacumab in Patients with Refractory Hypercholesterolemia

New England Journal of Medicine, 2020
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody ...
Daniel Gaudet, , Robert Pordy
exaly   +3 more sources

Evinacumab Therapy for Homozygous Familial Hypercholesterolemia

JACC: Advances, 2023
Peter Tóth
exaly   +2 more sources

Evinacumab to treat hypercholesterolemia

Drugs of Today, 2021
Cardiovascular disease is the most common cause of death worldwide and is mainly due to atherosclerosis. Elevated levels of low-density lipoprotein cholesterol (LDL-C) are the main risk factor for atherosclerosis. Treatment with existing therapies for dyslipidemia and life-style changes are often sufficient to reach the lipid targets and decrease the ...
C, Engler, C, Ebenbichler
openaire   +2 more sources